Akademik Veri Yönetim Sistemi
Klinik Gelisim, cilt.8, sa.2, ss.3516-3519, 1995 (Scopus)
Pre and post-treatment urinary GAG and β-NAG levels of 20 patients with hyperthyroidism were determined. Pre-treatment urinary GAG and β-NAG levels were 21.5 ± 2.5 mg/g kreatinin and 23.4 ± 12 U/g kreatinin, respectively. Post-treatment urinary GAG and β-NAG levels showed significant decrease (10 ± 3.5 mg/g kreatinin, 3.2 ± 1.6 mg/g kreatinin, respectively). Urinary B-NAG levels of NIDDM patients with nephropathy compared with the levels of hyperthyroidic patients levels as there were numerous investigations indicating that urinary β-NAG excretions increased in patients with terminal nephropathy. Pre-treatment β-NAG levels of patients with hyperthyroidism were significantly high than NIDDM patients with nephropathy (4.33 ± 1.2 U/g kreatinin). Although post-treatment β-NAG levels did not show any difference from the control levels the levels of NIDDM patients with nephropathy was same. According to our results, we could suggest that the decrease of urinary GAG and β-NAG levels of patients with hyperthyroidism in post-treatment is the consequence of the catabolic effects, rather than direct tubular influence of thyroid hormones. Therefore, GAG and β-NAG determination will be useful in the management of catabolic status of patients with hyperthyroidism.